Free Trial
NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Price, News & Analysis

Compass Therapeutics logo
$1.64
-0.07 (-4.09%)
(As of 10/31/2024 ET)

About Compass Therapeutics Stock (NASDAQ:CMPX)

Key Stats

Today's Range
$1.58
$1.71
50-Day Range
$1.19
$1.98
52-Week Range
$0.77
$2.34
Volume
515,657 shs
Average Volume
428,979 shs
Market Capitalization
$225.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67
Consensus Rating
Buy

Company Overview

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
64th Percentile Overall Score

CMPX MarketRank™: 

Compass Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 398th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Compass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Compass Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Compass Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.42) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Compass Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Compass Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Compass Therapeutics has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Compass Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.58% of the float of Compass Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Compass Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Compass Therapeutics has recently decreased by 11.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Compass Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Compass Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.58% of the float of Compass Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Compass Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Compass Therapeutics has recently decreased by 11.24%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Compass Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Compass Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Compass Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.50% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Compass Therapeutics' insider trading history.
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMPX Stock News Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Headlines

CMPX Stock Analysis - Frequently Asked Questions

Compass Therapeutics' stock was trading at $1.56 at the beginning of the year. Since then, CMPX stock has increased by 5.1% and is now trading at $1.64.
View the best growth stocks for 2024 here
.

Compass Therapeutics, Inc. (NASDAQ:CMPX) released its earnings results on Monday, August, 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $0.85 million for the quarter.

Compass Therapeutics (CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.

Compass Therapeutics' top institutional investors include Exchange Traded Concepts LLC (0.07%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends
.

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/12/2024
Today
10/31/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.67
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+377.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-42,490,000.00
Pretax Margin
-5,557.88%

Debt

Sales & Book Value

Annual Sales
$850,000.00
Book Value
$1.17 per share

Miscellaneous

Free Float
98,376,000
Market Cap
$220.83 million
Optionable
Not Optionable
Beta
0.90
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CMPX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners